AVANT

Regimen

Experimental
Bevacizumab + FOLFOX4, or Bevacizumab + XELOX
Control
FOLFOX4 alone

Population

Stage III or high-risk stage II colon cancer after curative resection (N=3,451), adjuvant bevacizumab plus chemotherapy.

Key finding

NEGATIVE and HARMFUL: DFS HR bev-FOLFOX4 vs FOLFOX4 = 1.17 (P=0.07, non-significant but numerically worse); OS HR 1.27 (P=0.02) for bev-FOLFOX4, suggesting potential detriment. First adjuvant trial to show possible OS harm from an added agent. Confirmed anti-VEGF has no adjuvant role.

Source: PMID 23168362

Timeline

    Guideline citations

    • NCCN Colon (p.99)